Cutaneous T-Cell Lymphoma

Pembrolizumab Combined with Radiotherapy Shows Promise in Advanced Cutaneous T-Cell Lymphoma: Final Results from UK NCRI Phase II Trial

By MedXY 08/10/2026

The UK NCRI phase II trial demonstrates pembrolizumab with localized radiotherapy yields meaningful response rates and durable control in relapsed/refractory advanced cutaneous T-cell lymphoma, marking an important step in improving outcomes for a challenging disease.

Dermatology Hematology-Oncology news

A New CTCL-Specific Quality-of-Life Tool Shows Strong Early Validity Signals in Cutaneous T-Cell Lymphoma

By MedXY 05/11/2026

A single-center validation study suggests the CTCL-PRO-20 may provide a reliable, disease-specific measure of quality of life in patients with cutaneous T-cell lymphoma.

Dermatology Hematology-Oncology news

Resminostat Maintenance Therapy Significantly Delays Disease Progression in Advanced Cutaneous T-Cell Lymphoma

By MedXY 02/17/2026

The RESMAIN trial demonstrates that resminostat maintenance therapy doubles median progression-free survival in patients with advanced mycosis fungoides or Sézary syndrome, offering a potential new standard for managing patients who have achieved disease control.

Dermatology Hematology-Oncology news

JAK2 Gene Fusions in Adult Patients with Mycosis Fungoides and CD30-Positive Lymphoproliferative Disorders: A Case Series

By MedXY 11/27/2025

This case series highlights the presence and clinical significance of JAK2 gene fusions across a spectrum of cutaneous T-cell lymphomas, including indolent and aggressive presentations.

Dermatology Hematology-Oncology news

T-Cell Receptor Clonotypes as Prognostic Markers in Cutaneous T-Cell Lymphoma: Insights from Next-Generation Sequencing

By MedXY 10/24/2025

This study identifies specific T-cell receptor clonotypes associated with aggressive subtypes and poorer survival in mycosis fungoides and Sézary syndrome, supporting TCR sequencing as a tool for refined risk stratification in cutaneous T-cell lymphoma.

$Innovative All-Oral Therapy: Linperlisib Plus Chidamide Shows Promise in Relapsed or Refractory Cutaneous T-Cell Lymphoma$

Clinical Updates Hematology-Oncology news Specialties

Innovative All-Oral Therapy: Linperlisib Plus Chidamide Shows Promise in Relapsed or Refractory Cutaneous T-Cell Lymphoma

By MedXY 09/03/2025

A phase 1 trial of linperlisib combined with chidamide demonstrated manageable safety and notable efficacy in relapsed/refractory CTCL, offering a potential new oral treatment option for advanced disease, especially mycosis fungoides.

$Linperlisib Plus Chidamide: A Promising Oral Therapy for Relapsed or Refractory Cutaneous T-Cell Lymphoma$

Clinical Updates Hematology-Oncology Specialties

Linperlisib Plus Chidamide: A Promising Oral Therapy for Relapsed or Refractory Cutaneous T-Cell Lymphoma

By MedXY 08/23/2025

This phase 1 trial demonstrates that linperlisib combined with chidamide offers manageable safety and noteworthy efficacy in relapsed or refractory cutaneous T-cell lymphoma, providing a potential new all-oral therapeutic option for advanced disease.